Antiplatelet Options for Patients with Atrial Fibrillation

Antiplatelet Options Based on Stroke Risk

• For patients with atrial fibrillation who choose not to take oral anticoagulants or no therapy, aspirin (75-325 mg once daily) is the recommended antiplatelet option, according to the American College of Chest Physicians 1
• Aspirin is preferred over combination therapy with aspirin and clopidogrel in low-risk patients (CHADS₂ score of 0), as recommended by the American College of Chest Physicians 2
• No therapy is actually suggested over antiplatelet therapy for truly low-risk patients, as stated by the American College of Chest Physicians 1
• Oral anticoagulation is recommended over antiplatelet therapy for intermediate risk patients (CHADS₂ score of 1), according to the American College of Chest Physicians 1
• For patients unsuitable for or choosing not to take oral anticoagulants, combination therapy with aspirin and clopidogrel is suggested over aspirin alone for intermediate risk patients (CHADS₂ score of 1), as recommended by the American College of Chest Physicians 1
• Oral anticoagulation is strongly recommended over any antiplatelet therapy for high risk patients (CHADS₂ score of ≥2), according to the American College of Chest Physicians 1

Special Clinical Scenarios

• For patients with atrial fibrillation and mitral stenosis who are unsuitable for or choose not to take adjusted-dose VKA therapy, combination therapy with aspirin and clopidogrel is recommended over aspirin alone, as suggested by the American College of Chest Physicians 3
• For patients with atrial fibrillation and coronary artery disease requiring anticoagulation, adjusted-dose VKA therapy alone is suggested over the combination of VKA and aspirin, according to the American College of Chest Physicians 4
• For high-risk stroke patients (CHADS₂ ≥2) during the first month after bare-metal stent or first 3-6 months after drug-eluting stent, triple therapy (VKA, aspirin, and clopidogrel) is suggested, as recommended by the American College of Chest Physicians 3
• For low to intermediate risk patients (CHADS₂ 0-1), dual antiplatelet therapy (aspirin and clopidogrel) is suggested during the first 12 months after stent placement, according to the American College of Chest Physicians 3
• For patients with atrial fibrillation and acute coronary syndrome without stent, dual antiplatelet therapy (aspirin and clopidogrel) is suggested for the first 12 months for low-risk stroke patients (CHADS₂ 0), as recommended by the American College of Chest Physicians 3
• For intermediate to high-risk patients (CHADS₂ ≥1) with atrial fibrillation and acute coronary syndrome without stent, adjusted-dose VKA plus single antiplatelet therapy is suggested, according to the American College of Chest Physicians 3

Important Caveats

• When choosing antiplatelet therapy, consider additional stroke risk factors beyond CHADS₂, including age 65-74 years, female gender, and vascular disease, as recommended by the American College of Chest Physicians 1